Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Accounts Payables (2016 - 2025)

United Therapeutics (UTHR) has disclosed Accounts Payables for 17 consecutive years, with $488.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 41.65% to $488.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $488.0 million through Dec 2025, up 41.65% year-over-year, with the annual reading at $488.0 million for FY2025, 41.65% up from the prior year.
  • Accounts Payables hit $488.0 million in Q4 2025 for United Therapeutics, up from $468.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $488.0 million in Q4 2025 to a low of $165.0 million in Q1 2021.
  • Historically, Accounts Payables has averaged $290.5 million across 5 years, with a median of $295.0 million in 2023.
  • Biggest five-year swings in Accounts Payables: decreased 6.63% in 2021 and later surged 51.48% in 2023.
  • Year by year, Accounts Payables stood at $174.6 million in 2021, then soared by 31.67% to $229.9 million in 2022, then grew by 29.62% to $298.0 million in 2023, then increased by 15.6% to $344.5 million in 2024, then soared by 41.65% to $488.0 million in 2025.
  • Business Quant data shows Accounts Payables for UTHR at $488.0 million in Q4 2025, $468.0 million in Q3 2025, and $432.0 million in Q2 2025.